ALXN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALXN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Alexion Pharmaceuticals has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.Alexion Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2021 was 30.48. Alexion Pharmaceuticals's debt to revenue ratio for the quarter that ended in Mar. 2021 was 0.41. As of today, Alexion Pharmaceuticals's Altman Z-Score is 5.10.
For the Biotechnology subindustry, Alexion Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Alexion Pharmaceuticals's Financial Strength distribution charts can be found below:
* The bar in red indicates where Alexion Pharmaceuticals's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Alexion Pharmaceuticals's Interest Expense for the months ended in Mar. 2021 was $-27 Mil. Its Operating Income for the months ended in Mar. 2021 was $826 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2021 was $2,560 Mil.
Alexion Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2021 is
Interest Coverage | = | -1 | * | Operating Income (Q: Mar. 2021 ) | / | Interest Expense (Q: Mar. 2021 ) |
= | -1 | * | 825.9 | / | -27.1 | |
= | 30.48 |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Alexion Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Mar. 2021 is
Debt to Revenue Ratio | = | Total Debt (Q: Mar. 2021 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (143.2 | + | 2559.6) | / | 6546 | |
= | 0.41 |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Alexion Pharmaceuticals has a Z-score of 5.10, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 5.1 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alexion Pharmaceuticals (NAS:ALXN) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
Alexion Pharmaceuticals has the Financial Strength Rank of 0.
Thank you for viewing the detailed overview of Alexion Pharmaceuticals's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Daniel Bazarko | officer: SVP, Controller, CAO | C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD BOSTON MA 02210 |
Tanisha Carino | officer: EVP & CCAO | C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210 |
Anne-marie Law | officer: EVP, Chief Experience Officer | C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015 |
Brian Goff | officer: EVP & Chief Commercial Officer | C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510 |
John J Orloff | officer: EVP, Research & Development | C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015 |
Indrani Lall Franchini | officer: EVP, Chief Compliance Officer | C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510 |
John T Mollen | director | 176 SOUTH STREET HOPKINTON MA 01748 |
David R Brennan | director | C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807 |
Baker Bros. Advisors (gp) Llc | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
L.p. 667, | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Andreas Rummelt | director | C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE CHESHIRE CT 06410 |
Francois Nader | director | 550 HILLS DRIVE, BEDMINSTER NJ 07921 |
Baker Brothers Life Sciences Lp | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Deborah Dunsire | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Judith A Reinsdorf | director | C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974 |
From GuruFocus
By GuruFocus Research GuruFocus Editor • 04-14-2021
By GuruFocus Research GuruFocus Editor • 06-21-2021
By GF Value GF Value • 04-04-2021
By PRNewswire PRNewswire • 03-06-2021
By PRNewswire PRNewswire • 04-30-2021
By Business Wire Business Wire • 05-12-2021
By GuruFocus Research GuruFocus Editor • 07-14-2021
By GF Value GF Value • 05-13-2021
By Business Wire Business Wire • 06-11-2021
By Business Wire Business Wire • 04-28-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.